Importance of antimicrobial stewardship to the English National Health Service

Jill Dixon
Christopher JA Duncan
Department of Infectious Diseases and Tropical Medicine, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, UK

Abstract: Antimicrobials are an extremely valuable resource across the spectrum of modern medicine. Their development has been associated with dramatic reductions in communicable disease mortality and has facilitated technological advances in cancer therapy, transplantation, and surgery. However, this resource is threatened by the dwindling supply of new antimicrobials and the global increase in antimicrobial resistance. There is an urgent need for antimicrobial stewardship (AMS) to protect our remaining antimicrobials for future generations. AMS emphasizes sensible, appropriate antimicrobial management for the benefit of the individual and society as a whole. Within the English National Health Service (NHS), a series of recent policy initiatives have focused on all aspects of AMS, including best practice guidelines for antimicrobial prescribing, enhanced surveillance mechanisms for monitoring antimicrobial use across primary and secondary care, and new prescribing competencies for doctors in training. Here we provide a concise summary to clarify the current position and importance of AMS within the NHS and review the evidence base for AMS recommendations. The evidence supports the impact of AMS strategies on modifying prescribing practice in hospitals, with beneficial effects on both antimicrobial resistance and the incidence of Clostridium difficile, and no evidence of increased sepsis-related mortality. There is also a promising role for novel diagnostic technologies in AMS, both in enhancing microbiological diagnosis and improving the specificity of sepsis diagnosis. More work is needed to establish an evidence base for interventions to improve public and patient education regarding the role of antibiotics in common clinical syndromes, such as respiratory tract infection. Future priorities include establishing novel approaches to antimicrobial management (eg, duration of therapy, combination regimens) to protect against resistance and working with the pharmaceutical industry to promote the development of new antimicrobials.

Keywords: antimicrobial resistance, antibiotics, National Health Service, methicillin-resistant Staphylococcus aureus, Clostridium difficile, prescribing

Introduction
Alongside vaccines and public health measures to control transmission of communicable diseases, antibiotics have helped to dramatically reduce mortality from infectious disease during the 20th century.¹ This success generated a sense of complacency among some figures in public health and academia in the 1960s and 1970s.² As Sir Frank Burnett, in accepting his Nobel prize for medicine in 1962, put it: “One can think of the middle of the twentieth century as the end of one of the most important social revolutions in history, the virtual elimination of the infectious diseases as a significant factor in social life.”³ However, the enduring global challenge of pathogens such as influenza, tuberculosis, and malaria, as well as the emergence of human...
immunodeficiency virus, means that infectious disease remains an important problem.⁴

The real value of antibiotics goes beyond simply preventing death and illness due to infection, in that antibiotics also permit the serious iatrogenic assault on the immune system occurring in cancer treatment or organ transplantation and have helped to keep surgical complication rates down.³ Therefore, antibiotics are an extremely valuable resource across the spectrum of modern medicine.⁶ However, the supply of new antibiotics has slowed dramatically, with only one or two agents targeting Gram-negative pathogens likely to be brought to market in the next decade.⁷

Antimicrobial stewardship
There is an urgent need to protect our current antimicrobial drugs for future generations.⁸ Antimicrobials can be conserved by judicious use to limit the development of antimicrobial resistance (AMR);¹⁰ this is the core component of antimicrobial stewardship (AMS).¹⁰ Additional benefits of AMS include preventing the selection of opportunistic pathogens such as Clostridium difficile,¹¹ limiting exposure to toxicities associated with misuse of antimicrobials,¹⁰ and direct economic savings through reduced complication rates and antimicrobial consumption.¹² AMS emphasizes sensible, appropriate antimicrobial management for the benefit of the individual and society as a whole.⁵,¹³

Antimicrobial resistance
There is a clear role for AMS in controlling AMR. Microorganisms invariably develop resistance in response to the evolutionary pressure exerted upon them by exposure to antimicrobials.¹⁴ This fact was recognized by Sir Alexander Fleming in his initial studies of the antibiotic properties of the Penicillium fungus. He cautioned, in his Nobel prize acceptance speech in 1945, that misuse of penicillin could contribute to development of AMR which could in turn compromise its usefulness. The history of treatment for Neisseria gonorrhoeae illustrates this point; the gonococcus has sequentially developed resistance against most antimicrobial drugs for future generations.⁸ Enterobacteriaceae such as Escherichia coli or Klebsiella species that are resistant to all but one or two antimicrobials have evolved as a consequence of extremely high levels of antibiotic exposure in several parts of the world, including Asia and the Middle East.¹⁷ Infections with these multidrug-resistant organisms are associated with approximately two-fold higher mortality rates and considerably prolonged hospital admissions.¹⁷ In 2009, the European Centre for Disease Prevention and Control estimated that AMR costs the European Union €1.5 billion in health care expenses and lost productivity per year.¹⁸ Nosocomial transmission has caused outbreaks in health care facilities, and international travel has facilitated global dissemination.¹⁷ A history of hospitalization overseas has become a personal risk factor for acquisition of multidrug-resistant organisms.¹⁹ In a recent survey, approximately one third of healthy travelers to Asia became asymptomatically colonized with multidrug-resistant Enterobacteriaceae despite low levels of health care contact.²⁰ Such asymptomatic carriage is also significantly higher in people in the UK from certain demographic groups with links to high incidence regions.²¹

However, there is cause for optimism that this threat can be contained. Some European countries, such as Sweden, have pioneered stewardship programs that have successfully reduced antibiotic use and kept AMR rates low.⁵ An AMS program in Scotland has had an important impact leaving multidrug-resistant N. gonorrhoeae isolates for which there are very few therapeutic options.¹⁵

This fearsome prospect of untreatable infection also applies to several other organisms. The Infectious Diseases Society of America has termed the main culprits the “ESKAPE pathogens” (Table 1), but the biggest global concern is AMR in Gram-negative bacteria. Enterobacteriaceae such as Escherichia coli or Klebsiella species that are resistant to all but one or two antimicrobials have evolved as a consequence of extremely high levels of antibiotic exposure in several parts of the world, including Asia and the Middle East.¹⁷ Infections with these multidrug-resistant organisms are associated with approximately two-fold higher mortality rates and considerably prolonged hospital admissions.¹⁷

### Table 1 ESKAPE pathogens

<table>
<thead>
<tr>
<th>Gram-positive</th>
<th>Gram-negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enterococcus faecium</td>
<td>Klebsiella species</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>Acinetobacter baumannii</td>
</tr>
<tr>
<td></td>
<td>Pseudomonas aeruginosa</td>
</tr>
<tr>
<td></td>
<td>Enterobacter species and Escherichia coli</td>
</tr>
</tbody>
</table>

**Note:** Data from Boucher et al.¹⁴

### Table 2 UK 5 year antimicrobial resistance strategy 2013–2018

<table>
<thead>
<tr>
<th>Strategic aims</th>
<th>Improve the knowledge and understanding of AMR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Conserve and steward the effectiveness of existing treatments</td>
</tr>
<tr>
<td></td>
<td>Stimulate the development of new antibiotics, diagnostics, and novel therapies</td>
</tr>
<tr>
<td>Seven key areas for action</td>
<td>Optimizing prescribing practice</td>
</tr>
<tr>
<td></td>
<td>Improving infection prevention and control practices</td>
</tr>
<tr>
<td></td>
<td>Improving professional education, training, and public engagement</td>
</tr>
<tr>
<td></td>
<td>Developing new drugs, treatments, and diagnostics</td>
</tr>
<tr>
<td></td>
<td>Better access to and use of surveillance data</td>
</tr>
<tr>
<td></td>
<td>Better identification and prioritization of AMR research needs</td>
</tr>
<tr>
<td></td>
<td>Strengthened international collaboration</td>
</tr>
</tbody>
</table>


**Abbreviation:** AMR, antimicrobial resistance.
on antimicrobial consumption and *C. difficile* rates.\(^2\) AMS programs also appear to have had a significant impact in the English hospital setting.\(^7\) The incidences of both methicillin-resistant *Staphylococcus aureus* and *C. difficile* peaked in the mid 2000s, and it is believed that a combination of restrictive antimicrobial policies and better infection prevention and control practices (eg, source isolation and handwashing) were responsible for the decreasing incidence of both infections,\(^5\) although it is not clear which of these interventions had the dominant role. At the global level, the problem of AMR in England is comparatively minor at present. However, with a relatively narrow focus on methicillin-resistant *S. aureus* and *C. difficile*, the growing problem of bacteremia due to other multidrug-resistant organisms has been largely ignored.\(^7\)

AMR is an emergent threat to health care delivery within the National Health Service (NHS) in England.\(^7\) A multiplicity of government documents, recommendations, and position statements on AMS to address AMR in the English NHS have been produced over the last few years. Here we provide a timely summary of these publications to help clarify the current position and importance of AMS to the NHS in England. We outline the evidence base underpinning the AMS recommendations, and conclude with a discussion of future priorities.

**Antimicrobial stewardship initiatives in the NHS**

Concerns regarding the rise of AMR and the priority of AMS were recently highlighted by the Chief Medical Officer, Dame Sally Davies, in her annual report of 2011, published in March 2013.\(^3\) This report received a lot of attention and provided much needed focus for AMS leadership.\(^7\) The report addressed four broad areas of AMS:\(^13\)

- Concerns about global AMR
- The need to raise awareness and education about AMR among the public and within the NHS
- The need for better surveillance systems for AMR
- The need to improve diagnostics.

In parallel with the Chief Medical Officer’s report, a UK pan-governmental strategy and action plan for AMR has been recently published (see Table 2).\(^2\) However, awareness of AMR in the UK is not a recent development; a series of reports and policy initiatives has addressed AMR in the NHS over the last two decades, as summarized in Table 3. “The Path of Least Resistance” (1998)\(^2\) first outlined the AMS imperatives for the NHS. Introducing several stewardship themes that are recognizable in subsequent reports, it highlighted the need for antimicrobial prescribing to be evidence-based and supported by national formularies, and emphasized the need for antimicrobial prescribing to take a more prominent place in medical education, to utilize the expertise of infection specialists, and for resources to be directed towards research into developing strategies to combat AMR.\(^2\)\(^4\) Following this, the UK Department of Health produced several reports on AMR/AMS, starting with the first UK “Antimicrobial Resistance Strategy and Action Plan” in 2000.\(^2\)\(^5\) The Health and Social Care Act 2008\(^2\)\(^6\) provided a framework for the Care Quality Commission to objectively measure the quality of health care provision, and specifically included AMS outcomes. Criterion 9 states: “Procedures should be in place to ensure prudent prescribing and antimicrobial stewardship.”

There should be an ongoing program of audit, revision, and update. In health care, this is usually monitored by the antimicrobial management team or local prescribing advisors. To provide practical guidance for NHS providers, the Antimicrobial Stewardship in Primary Care collaboration was formed in 2009. This multiagency collaboration produced a multifaceted AMS intervention for primary care that was launched in 2012. The Treat Antibiotics Responsibly, Guidance and Education Toolkit (TARGET)\(^2\)\(^7\) contains evidence-based resources for clinician and patient education, as well as specific antimicrobial guidance and self-assessment and audit tools. Also in 2012, the Department of Health’s Advisory Committee on Antimicrobial Resistance

| Table 3 Key antimicrobial stewardship initiatives in the National Health Service |
|-------------------------------------|------------------|---------------------|
| Report                             | Year  | Agency                          |
| The Path of Least Resistance       | 1998  | Medical Advisory Committee      |
| UK Antimicrobial Resistance Strategy and Action Plan | 2000  | Department of Health            |
| Winning ways: Working together to reduce Healthcare Associated Infection | 2003  | Department of Health            |
| The Health Act                     | 2006  | Department of Health            |
| Saving Lives: Reducing Infection, Delivering Clean and Safe Care | 2007  | Department of Health            |
| Health and Social Care Act: A Code of Practice on the Prevention and Control of Infections | 2008  | Department of Health            |
| TARGET toolkit                     | 2009  | Antimicrobial Stewardship in Primary Care |
| Start Smart then Focus             | 2012  | Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection |
| English Surveillance Programme for Antimicrobial Utilization and Resistance | 2013  | Public Health England          |

**Abbreviation:** TARGET, Treat Antibiotics Responsibly, Guidance and Education Toolkit.
and Healthcare Associated Infection produced the “Start Smart and Focus” guidance\(^1\) to provide a framework for best antimicrobial prescribing practice. Included within Start Smart and Focus is the Acute Hospital’s Assessment Tool,\(^2\) an evidence-based checklist for AMS assessment and audit. Overall, these publications aim to standardize the practice of AMS across the NHS in England in both primary and secondary care settings.

**Antimicrobial prescribing in the NHS**

It is challenging to accurately assess current prescribing patterns across the NHS in England. Whilst the Health and Social Care Information Centre monitors antimicrobial dispensing data in primary care, there is no routine public reporting of antimicrobial use in hospitals.\(^29\) For this, we must rely on intermittent antibiotic point prevalence surveys, such as that done in 2011 by the Health Protection Agency.\(^3\) Within the NHS, most antimicrobial prescribing (up to 80%) happens in primary care. However, despite awareness of the problem of resistance and the raft of AMS reports discussed above (Table 3), there was a 16% increase in antimicrobial prescriptions in primary care between 2002 and 2012.\(^29\) The “NHS Atlas of Variation in Health Care” also describes a three-fold variation in quinolone prescriptions and an 18-fold variation in cephalosporin prescriptions across primary care trusts in England in 2010.\(^1\) Such regional variation also applies to inpatient antimicrobial prescriptions (which vary in the range of 29%–39.9% for inpatients) and seems not to be driven solely by demographic factors or regional variation in burden of disease.\(^5\)

**Surveillance**

More detailed understanding of patterns of antimicrobial use will be of central importance when directing and assessing the impact of AMS programs in England. As a result, Public Health England has developed the English Surveillance Programme for Antimicrobial Utilization and Resistance to monitor antimicrobial prescribing and resistance in primary and secondary care.\(^29\) The English Surveillance Programme for Antimicrobial Utilization and Resistance also has the remit to develop quality measures and methods to monitor unintended outcomes of AMS and educational/behavioral interventions.\(^29\)

**Education and training**

The desire for more training in antimicrobial prescribing has been identified in surveys of both doctors in training\(^30\) and medical students.\(^31\) Trainee doctors generally view comprehensive antimicrobial prescribing guidelines positively,\(^30\) although surveys continue to show that when prescriptions are noncompliant with guidelines, the antibiotic choice tends to be broader spectrum but not more appropriate to the organism,\(^32\) suggesting that efforts to improve adherence with guidelines are warranted. Growing recognition that the principles of antimicrobial prescribing and stewardship are central to the practice of medicine in the UK has led to the development of specific antimicrobial prescribing competencies within a 2012 report entitled “A single competency framework for all prescribers”,\(^33\) developed by the National Prescribing Centre on behalf of the National Institute for Clinical Excellence, which has been endorsed by the General Medical Council and the Academy of Medical Royal Colleges. To complement the National Prescribing Centre competency framework, five specific antimicrobial prescribing and stewardship competencies have been recently released by the Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection.\(^34\) These cover infection prevention and control, AMR, antimicrobial prescribing, AMS, and monitoring and learning. The need for better education and training does not just apply to health care professionals. As consumers of antimicrobials, it is vital to engage patients and members of the public in AMS campaigns.

**Public engagement**

Public misconceptions about the role of antibiotics in viral infections\(^35\) indicate a need for better education, and surveys have shown that among various reasons cited by practitioners for inappropriate antibiotic prescriptions, patient expectation was highly influential.\(^36,37\) Annual European Antibiotic Awareness Days (EAAD) aim to improve public understanding about the appropriate role for antibiotics in common clinical scenarios.\(^38\) However, in a recent survey performed in conjunction with EAAD, approximately 35% of those surveyed in the UK were unaware that antibiotics have no effect in viral infection.\(^38\) Some interventions such as the English 2008 poster-based EAAD educational program had a negligible impact on antimicrobial knowledge or consumption.\(^39\) However, other simple practical measures such as an interactive booklet on respiratory infections in children supplied in primary care have been shown to significantly reduce antibiotic prescriptions without reducing parental satisfaction;\(^40\) this booklet is included in the TARGET toolkit.\(^27\) Whilst the need for better patient education about the role of antibiotics is widely acknowledged,\(^9,12,13\) there is also a need for more evidence-based guidance about how best to achieve this. However, the main focus...
of AMS is on reducing antimicrobial prescribing by health care professionals, and we summarize evidence for such interventions below.

**Evidence base for AMS interventions**

**Primary care**

A variety of heterogeneous AMS interventions in the primary care setting have been evaluated. The main objective is to reduce antimicrobial prescribing for various infections, particularly respiratory tract infection (which is most commonly viral) as well as uncomplicated urinary tract infection and otitis media, or reducing the prescription of specific agents. A previous Cochrane review indicated that multifaceted interventions tailored to precise target populations were most likely to have significant effects on prescribing. Recent randomized controlled trials have evaluated multifaceted interventions with positive effects on reducing antibiotic prescribing rates. However, few studies have been sufficiently powered, designed, or tested interventions with sufficient effect sizes to show an impact on AMR.

**Secondary care**

The effectiveness of AMS interventions on inpatient prescribing has been the subject of a recently updated Cochrane systematic review and meta-analysis. Intervention studies have evaluated the effect of persuasive interventions (including circulation of educational material, educational meetings, and audit and feedback) and restrictive measures (including reporting selective antimicrobial sensitivities, formulary restrictions, and mandatory prior infection specialist approval for certain drugs) in reducing inappropriate antimicrobial prescriptions. The majority of interventions (in 84% of studies) focused on the antimicrobial prescribed, whereas the remainder addressed whether or not antibiotics should be prescribed at all. Both restrictive and persuasive interventions were effective in randomized controlled trials (median effect size 40.5% versus 24.7%, respectively). In a meta-analysis of 52 studies, restrictive interventions had significantly greater impact on prescribing outcomes at one month (32%, 95% confidence interval [CI] 2–61, *P* = 0.03) and on microbial outcomes at 6 months (53%, 95% CI 31–75, *P* = 0.001) but there were no significant differences at 12 or 24 months. Several beneficial outcomes were associated with reduced antimicrobial prescribing (regardless of how it was achieved), such as reduced *C. difficile*, methicillin-resistant *S. aureus*, and extended spectrum beta-lactamase *Enterobacteriaceae* rates. In addition, whilst there was no clinical evidence of increased mortality in nine studies aimed at reducing antibiotic exposure, four studies focusing on optimizing prescribing for community-acquired pneumonia showed a significant improvement in mortality (risk ratio 0.89, 95% CI 0.82–0.97). Overall, these data indicate that AMS interventions are effective and evidence-based, and support restrictive interventions when short-term improvements are required.

**Diagnostics**

Delay in administering effective antibiotics results in stepwise increases in mortality resulting from bacterial sepsis. From the perspective of AMS this presents a paradox, given that as AMR becomes more prevalent the need for clinicians to use empirical broad spectrum antibiotics in patients with severe sepsis will become greater, driving selection of resistant microorganisms and exacerbating the problem. Strategies to improve the diagnosis of serious infection with multidrug-resistant organisms are a particular focus of AMS programs to guide the appropriate use of broad-spectrum therapy and avoid unnecessary antibiotic exposure. The role for novel diagnostic technologies lies in rapid identification of causative organisms (which permits targeted, narrow-spectrum therapy), as well as in improving the specificity of sepsis diagnosis (given that many patients with a systemic inflammatory response do not have serious bacterial infection and therefore do not require antibiotic therapy). Developments in this field are the subject of a recent review.

**Biomarkers**

The use of biomarkers has been shown to aid the clinical diagnosis of infection and to reduce unnecessary antibiotic prescriptions. For example, the inclusion of the biomarker procalcitonin in an antibiotic management algorithm has been shown in randomized controlled trials and in pragmatic clinical trials to safely reduce the frequency and duration of antibiotic therapy for suspected lower respiratory tract infection, and to enhance de-escalation of broad-spectrum antibiotics in cancer patients and critical care patients with infection. In a recent meta-analysis, procalcitonin combined with careful clinical assessment had a sensitivity of 0.77 and specificity of 0.79 for the diagnosis of sepsis compared with systemic inflammatory response of noninfective etiology and therefore do not require antibiotic therapy. Developments in this field are the subject of a recent review.

Importance of antimicrobial stewardship to the English NHS
Algorithms incorporating newer biomarkers, alone or in combination, are also under investigation, but more data are required before their definitive role can be established.

**Rapid microbiological diagnosis**

Current microbiological diagnosis is inefficient, with a minimum lag of 48 hours between the isolate reaching the laboratory and accurate organism identification. Molecular techniques have the potential to greatly speed up microbiological diagnosis and could also be used to detect genomic resistance, thus reducing exposure to unnecessary broad-spectrum antibiotics. With sufficient sensitivity, they could also play a part in determining whether antibiotics need to be prescribed or not. These techniques broadly involve either proteomic or genomic methods.

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) detects the proteomic signature of an array of pathogens, and can yield diagnostic information in a matter of minutes. The utility of MALDI-TOF in the AMS setting has been demonstrated in proof of concept studies. However, technical issues currently preclude its more widespread application, such as difficulties in distinguishing certain bacterial species and problems identifying polymicrobial infections.

Additional molecular techniques, such as nucleic acid amplification or nucleic acid hybridization, are in clinical use for pathogen detection (eg, identifying *N. gonorrhoeae, Chlamydia trachomatis, C. difficile*, and several other pathogens). Rapid nucleic acid amplification kits can also identify resistance mutations, such as the mecA gene in methicillin-resistant *S. aureus*. Next-generation whole genome sequencing has greater potential applicability to AMS, in view of its ability to simultaneously identify several pathogens as well as potential resistance mutations, as well as its ability to provide early indications of outbreaks through analysis of the relatedness of pathogen genomes in different patients. However, much work remains before these technologies are available for cost-effective routine diagnostic applications.

**Conclusion and outstanding challenges**

In this review, we have outlined the current status of AMS in the English NHS, including national policies and guidance, the evidence base for intervention strategies, and issues of education, training, and improved diagnostic technologies. However, there are a number of outstanding challenges in the field of stewardship and AMR.

One important strategy to combat the potential threat of untreatable infection is to accelerate the development of novel antimicrobials, although this is unlikely to happen without extensive commercial and/or political incentives, such as tax breaks, government funding, financial rewards for specific outcomes, simplified regulatory requirements, or extended patents. One such example is the 2012 US Generating Antimicrobial Incentives Now (GAIN) Act. Clearly, AMS will remain of critical importance to protect any future antimicrobials developed through such effort.

Another priority for future work is to define the optimal duration of antimicrobial prescribing, for example, whether antibiotic conservation through short-duration regimens is safe and effective in limiting the development of resistance. Additional strategies that have been suggested include the use of combinations of antibiotics from different classes (as is used in antiretroviral therapy for human immunodeficiency virus) or the cycling of first-choice antibiotics in empirical prescribing guidelines to avoid prolonged exposure.

Here we have summarized the current status and importance of AMS to the NHS in England, and outlined the evidence base for current and potential AMS programs. The ultimate success of AMS may well determine to a large degree the future scope, utility, and effectiveness of the English NHS.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


